detomidine topical (CLE-400) / Clexio Biosci - LARVOL DELTA

CLE400-NP-201: A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects with Notalgia Paresthetica (clinicaltrials.gov) - P2 | N=59 | Completed | Sponsor: Clexio Biosciences Ltd. | Recruiting ➔ Completed

Trial completion • Dermatology • Pruritus

CLE-400: Topical α2-Adrenergic Agonist Being Developed as a Novel Mechanism for Treating Chronic Pruritus Associated with Notalgia Paresthetica (EADV 2024) - "Materials & CLE-400 antipruritic effect was examined in the chloroquine-inducted itch model in mice. CLE-400 has demontrated anti pruritic and analgesic effects in preclinical models. Phase 1 study results supported proceeding to Phase 2, to further assess the efficacy and safety of CLE-400 in Notalgia Paresthetica patients. While α 2 adrenergic agonists are well established as systemic treatment of cardiovascular and psychiatric disorders , this trial of CLE-400 for Notalgia Parasthetica represents the first clinical study of this mechanism of action for the topical treatment of chronic, localized pruritus."

Cardiovascular • CNS Disorders • Dermatology • Mental Retardation • Mood Disorders • Pain • Peripheral Neuropathic Pain • Pruritus • Psychiatry

Turmeric extract alleviates airway inflammation via oxidative stress-driven MAPKs/MMPs pathway. (PubMed, Int Immunopharmacol) - "CLE (100 or 300 mg/kg/day) was orally administered daily from days 18 to 23, with dexamethasone (3 mg/kg/day) used as the positive control...The CLE100 and CLE400 groups exhibited a significant downregulation in eosinophil counts, cytokine levels, and immunoglobulin-E levels...Additionally, 50 µg/mL CLE and 2.5 µg/mL curcumin showed similar anti-inflammatory effects. Collectively, our findings revealed that CLE could suppress airway inflammation in asthmatic mice and A549 cells via oxidative stress-driven MAPK/MMPs signaling, suggesting that CLE could be developed as a potential treatment option for patients with asthma."

Journal • Asthma • Immunology • Inflammation • Oncology • Pulmonary Disease • Respiratory Diseases • MMP2 • MMP9 • TNFA

CLE400-NP-201: A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (clinicaltrials.gov) - P2 | N=54 | Recruiting | Sponsor: Clexio Biosciences Ltd. | N=40 ➔ 54

Enrollment change • Dermatology • Pruritus

CLE400-NP-201: A Study of CLE-400 (Topical Gel) for the Treatment of Chronic Pruritus in Adult Subjects With Notalgia Paresthetica (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Clexio Biosciences Ltd.

New P2 trial • Dermatology • Pruritus